Starting in September, the NHS will extend its RSV vaccination programme to include adults aged 65 to 74 with chronic respiratory conditions or weakened immune systems. This change is significant as it targets individuals at heightened risk of severe illness from respiratory syncytial virus (RSV), which can lead to serious complications like pneumonia and bronchitis.
The decision follows guidance from the Joint Committee on Vaccination and Immunisation, highlighting the need for increased protection among vulnerable populations. Eligible individuals can receive the vaccine through local GP surgeries or select high street pharmacies, making access more convenient.
RSV is a major public health concern, hospitalising around 14,000 people annually and causing approximately 8,000 deaths. The virus typically peaks during colder months, but health officials warn that it poses a risk year-round, underscoring the importance of vaccination.
Public health officials believe that this expansion will not only save lives but also alleviate pressure on the NHS during winter months, when hospital admissions typically surge. The programme has already shown success, with over half a million vaccinations administered to those aged 80 and above in recent months.
Source: GB News
